Key Takeaways from RAPS Euro Convergence: Advancing Regulatory Practices

The RAPS Euro Convergence Conference proved to be an exceptional gathering of regulatory professionals, offering an unparalleled level of sessions and workshops. This highly educational event served as the ultimate destination for regulatory experts seeking comprehensive insights and the latest updates in the field. With its remarkable content and esteemed participants, the conference exceeded expectations and solidified its status as a must-attend event for regulatory professionals.

Insights from RAPS Euro Convergence

In this blog, we will be sharing some of the highlights our regulatory affairs team learned from this enlightening event. 

Sustainability in medical devices: promoting a greener healthcare industry  

The team was impressed by the presentation “Updates on ‘Sustainable’ Medical Devices Emphasis” given by Kati Agostino and Michelle Sullivan. In this presentation, it was clear that the need for sustainability within the medical device industry has become increasingly apparent, driven by the need to minimize environmental impact, reduce resource consumption, and promote a more circular economy. A surprising and worrying statement was made during the session: “If the healthcare industry were a country, it would be the fifth-largest emitter on the planet.” With that, it was clear that the stakeholders within the medical devices industry need to include sustainable design and operational processes immediately. This sentiment was supported by the examples given by the NHS, which, within its procurement processes, require suppliers to reduce their emissions.

From our side, we encountered more and more companies being pressed to assess the environmental impacts of their products by considering the entire life cycle. These pressures are leading to the use of tools that promote fact-based environmental decision-making toward a more sustainable health sector. An example of this is that more and more tenders require manufacturers to have an ISO 14001 Environmental Management Certification in place.   

Balancing MDR data gathering and GDPR limitations

The General Data Protection Regulation (GDPR) is arguably one of the crucial pieces within the EU legislative framework that Manufacturers and end-users may sometimes forget. Considering this, the team found highly insightful the presentation provided by Erik Vollebregt, Leo Hovestadt et al. on “Data privacy & digital health: medical devices, IVDs and the increasing EU Regulation of health data.” The presentation focused on the relevance of GDPR and its relationship with the MDR during the lifecycle of a medical device, from clinical investigation data to post-market surveillance. It demonstrated how manufacturers might falsely believe that MDR obligations manifest personal data processing as lawful and in compliance with the GDPR. However, as identified during the presentation, this is not always the case. It is crucial, as stated, that manufacturers understand that “each processing of personal data requires a legal basis and, especially in the case of health data, the exception to the general prohibition of processing such data is identified” – thus, a balancing act of two Regulations is required.

This makes one wonder how manufacturers are currently complying with the MDR and GDPR while considering the patient’s best interest and safety. Additionally, how will the introduction of the European Health Data Space (EHDS) shape and develop the growing digital space while upholding the privacy of one’s health data? Although the proposal of the EHDS provides an initial sense of relief regarding the development of privacy laws within the medical field, the presentation demonstrated that legal challenges will still be encountered with the current proposal considering the growing relevance of cybersecurity for medical devices. 

SAMD and AI clinical evidence

During the session at RAPS Euro Convergence on “AI/machine learning based medical software: case studies on model development and regulatory compliance,” manufacturers were provided with valuable insights into the challenges they face in meeting AI clinical evidence requirements.

Challenges faced by manufacturers

Based on the session, we have identified six key challenges that manufacturers encounter:

• • • The “AI/machine learning based medical software: case studies on model development and regulatory compliance” session was a hot topic and gave us an insightful overview of the challenges Manufacturers face in meeting AI clinical evidence requirements. We took what we believe to be the top 5 challenges from the session and explained them below:   
    • Biased AI: The presence of bias in AI algorithms can perpetuate disparities and inequities in healthcare. Manufacturers must address bias in AI systems and strive for fairness and inclusivity. Robust data selection, algorithm validation, and continuous monitoring are essential to minimize bias and ensure equitable outcomes for all patient populations.  
    • Generalizability of ML Identifications, Predictions, and Recommendations: The ability of machine learning (ML) algorithms to generalize findings across diverse patient populations is still a matter of concern. Establishing the reliability and validity of AI-generated identifications, predictions, and recommendations for different demographic groups remains a challenge that demands further research and validation.  
    • Data Quality and Quantity: The performance of AI systems heavily relies on the quality and quantity of the data used for training and validation. Acquiring sufficient and relevant data, while ensuring its integrity, privacy, and consent is a complex task. Manufacturers must carefully consider data acquisition strategies and establish robust processes to manage and curate datasets effectively.  
    • Privacy Issues (GDPR Challenge): The GDPR poses significant challenges in the context of AI implementation. Safeguarding patient privacy, ensuring informed consent, and managing data anonymization and pseudonymization are critical aspects that manufacturers must address to comply with privacy regulations while leveraging AI technologies.   
    • Patient Design is Not Considered: Involving patients in the design and development of AI-enabled medical devices is often overlooked. Considering patient perspectives, needs, and usability can enhance the effectiveness and acceptance of these devices. Manufacturers should prioritize patient-centered design methodologies to create user-friendly and patient-centric AI solutions.  

As a conclusion from the session, we strongly encourage manufacturers to consider all points mentioned above while performing risk management.   

The rise of real-world evidence: its significance for manufacturers

We greatly appreciate the enlightening session on real-world evidence (RWE) at RAPS Euro Convergence and its relevance for manufacturers of medical devices. The session started by pointing out the absence of a formal definition of RWE in the MDR and the MDCG documents, referring, therefore, to a definition provided by ChatGPT: “data and information collected outside of the controlled environment of a clinical trial.” This definition encompasses data gathered from routine clinical practice, patient registries, electronic health records, claims databases, and other healthcare sources. The session highlighted not only the reasons why RWE is significant but also the increasing interest manufacturers have shown in RWE. As we all know, manufacturers encounter challenges in obtaining sufficient data, especially for less common indications. 

Additionally, they often face difficulties acquiring clinical investigation or literature data, even for commonly used devices with extensive market history. Therefore, RWE offers an efficient means for manufacturers to collect data from retrospective sources and prospectively gather data through established usage. It plays a crucial role in post-market surveillance activities, enabling manufacturers to monitor device performance in real-world conditions, identify potential safety concerns, and make informed decisions regarding device modifications or recalls. Furthermore, by analyzing real-world data, manufacturers can enhance their understanding of device-associated risks, supporting proactive risk management practices. Using real-world data provides valuable insights that complement traditional clinical trial data, fostering a more comprehensive understanding of device safety and effectiveness. 

Expert panel outcomes: key insights from ten opinions

This session was new to us and very insightful. We are pleased to share the valuable insights from the Expert Panel, which has provided ten opinions thus far. According to Article 54 (1) of the Medical Device Regulation (MDR), specific devices may fall under the scope of the Clinical Evaluation Consultation Procedure (CECP) as part of their conformity assessment. Class III implantable devices or Class IIb devices (as per Rule 12 of the ARMS) may be subject to the CECP. During the presentation, the expert panel highlighted that the majority of concerns expressed in these ten opinions relate to insufficient evidence, an issue that the MDR aims to address by rectifying past errors. Emphasizing the significance of thorough clinical evaluations, they stressed that manufacturers and notified bodies must carefully consider all opinions to provide more robust support for these evaluations. 

Furthermore, the presentation underscored the importance of incorporating the concept of “state of the art” into your Clinical Evaluation Report (CER), making it a focal point. We strongly recommend that manufacturers of devices classified under the CECP’s risk category diligently monitor the expert panel opinions to anticipate potential concerns from manufacturers and assist in aligning the expectations of notified bodies. By staying informed and actively engaging with the expert panel opinions, manufacturers can not only anticipate potential concerns but also aid notified bodies in refining their expectations, ensuring a smoother and more effective conformity assessment process: List of opinions provided under the CECP (Europa.eu) 

Evolving regulatory landscape

As MedEnvoy, we are delighted with the knowledge and insights gained from RAPS Euro Convergence. It has provided us with a deeper understanding of critical topics and challenges in the regulatory landscape. We express our gratitude to RAPS for organizing such an exceptional event, and we eagerly look forward to the next conference. We are committed to staying informed and keeping these topics in our radar, making them a focal point as we continue to navigate the evolving regulatory environment and serve our clients with the utmost diligence and expertise.

RAPS Euro Convergence Recap

Intrigued by the wealth of knowledge and insights shared at the RAPS Euro Convergence Conference, we invite you to explore our website and meet our exceptional regulatory affairs/quality assurance team. From the pressing need for sustainability in the medical device industry to the complex balancing act between MDR data gathering and GDPR limitations, we’ve gained valuable insights that can help navigate these challenges.

MedEnvoy is a professional, third-party provider of in-country representation and regulatory compliance importer services for medical device and IVD manufacturers. We help you comply with EU MDR and IVDR, the UK MDR regulations and Swiss regulations.

If you have any further questions or want to delve deeper into these topics, don’t hesitate to reach out to us. We’re here to provide guidance and expertise in this ever-evolving regulatory landscape. Contact us today!